Drugs / SCIB1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01138410 | May 2010 → Jul 2017 | melanoma | Scancell Ltd | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04079166 | Aug 2019 → Jan 2027 expected | cutaneous melanoma | Scancell Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCIB1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01138410 ↗ |
| Modality | Vaccine | “SCIB1 or iSCIB1+ DNA vaccine” NCT04079166 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT01138410 ↗ |